PharmAsia News
Insider Analysis from Sidley Austin LLP: Market Definition in Life Sciences Sector Under the Chinese Anti-Monopoly Law
September 22, 2008
China’s Anti-Monopoly Law, in force since Aug. 1, raises difficult questions for market players in the health care industry in China. One issue of particular importance is how to define the “relevant market” for medicinal products.
Contacts
Capabilities
Suggested News & Insights
Digitalization Instructions for Use EU Issues Updated Framework for eIFUs of Medical DevicesMay 19, 2021NICE Moves to Drive UK Digital Health InnovationMay 17, 2021EU Publishes Guidance on Clinical Investigations to Help Sponsors’ Compliance with MDRMay 5, 2021Statutory Change to New Chemical Entity Exclusivity Provision May Have Impacts for Scope of Patent Term ExtensionApril 30, 2021FDA Releases Guidance on Remote Interactive Evaluations During COVID-19April 21, 2021FDA’s COVID-19 Facility Inspection Backlog: Likely Reinspection Delays Emphasize Importance of Facility ReadinessApril 14, 2021
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory